CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) . CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP + -induced cytotoxicity through activation of the Keap1-Nrf2
CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) . CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP + -induced cytotoxicity through activation of the Keap1-Nrf2
CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) . CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP + -induced cytotoxicity through activation of the Keap1-Nrf2
CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) . CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP + -induced cytotoxicity through activation of the Keap1-Nrf2
CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) . CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP + -induced cytotoxicity through activation of the Keap1-Nrf2
CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) . CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP + -induced cytotoxicity through activation of the Keap1-Nrf2
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >:30-fold selectivity against NHE2 and with
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >:30-fold selectivity against NHE2 and with
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >:30-fold selectivity against NHE2 and with
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >:30-fold selectivity against NHE2 and with
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >:30-fold selectivity against NHE2 and with
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >:30-fold selectivity against NHE2 and with
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >:30-fold selectivity against NHE2 and with
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >:30-fold selectivity against NHE2 and with
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >:30-fold selectivity against NHE2 and with
BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC 50 s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >:30-fold selectivity against NHE2 and with